Olysio gets EU CHMP nod as it trails Sovaldi onto EU market
This article was originally published in Scrip
Executive Summary
Janssen-Cilag's hepatitis C NS3/4A serine protease inhibitor Olysio (simeprevir) has been given the green light for marketing by the EU's CHMP at its latest meeting on 20 March.